Secured $96M Series C Financing; Total Raised Since 2019 Founding Exceeds $450M Proceeds Fund the Clinical Development of TORL-1-23, Currently in a Registrational Phase 2 Study for Claudin 6 Positive (CLDN6+) Platinum-Resistant Ovarian Cancer and in Phase 1 for other CLDN6+ Cancers...
Hence then, the article about torl biotherapeutics secures 96m series c financing and presents updated phase 1 results of novel claudin 6 targeted antibody drug conjugate torl 1 23 at the 2025 european society of medical oncology congress was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( TORL BioTherapeutics Secures $96M Series C Financing and Presents Updated Phase 1 Results of Novel Claudin 6 Targeted Antibody-Drug Conjugate TORL-1-23 at the 2025 European Society of Medical Oncology Congress )
Also on site :
- Disgraced former Centinela Valley schools Superintendent Jose Fernandez dies
- Tyler Perry Sued for Sexual Assault By New Accuser, an Actor in a ‘Madea’ Movie
- New law revives dormant plans for solar plant near Mojave National Preserve